Clinical Trial Update: Topical Bevacizumab for Preventing Recurrent Pterygium [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating topical bevacizumab to prevent recurrent pterygium has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium

Drugs mentioned

• Avastin (bevacizumab) (bevacizumab)

Snippet

Sponsor: Chulalongkorn University | Conditions: Pterygium, Bevacizumab | Phase 3 | Status: COMPLETED